Autologous stem cell transfusions on multiple days in patients with multiple myeloma—Does it matter?

Sebastian Moser(University of Bern), Thomas Pabst(University Hospital of Bern), Axel Ruefer(Luzerner Kantonsspital), Ulrike Bacher(Hattiesburg Clinic), Urban Novak(University of Bern), Thomas Egger(Solothurner Spitäler), Daniel Betticher, Behrouz Mansouri Taleghani(University of Bern), Barbara Jeker(University of Bern)

Hematological Oncology

September 4, 2019

10.1002/hon.2673

Cited by 3

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2019|3.4k

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients

|Blood|2007|410

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

|The Lancet|2015|392

Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer

|British Journal of Cancer|1996|220

Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome

|Blood|2010|189